Nicole Therese Eiseler, MD

Rohan Garje, M.D., is a nationally renowned medical oncologist and the chief of genitourinary medical oncology at Miami Cancer Institute. Dr. Garje specializes in the treatment of prostate, kidney, bladder, testicular and penile cancer. Dr Garje has significant expertise in the design of novel investigator-initiated clinical trials and has served as the principal investigator for numerous phase I, II and III clinical trials. He focuses on providing precision oncology care utilizing targeted therapy, hormonal therapy, immunotherapy, radioligand therapy and chemotherapy. Dr. Garje is an internationally published leader in cancer research. He has amassed over 30 publications in prestigious journals, such as Journal of Clinical Oncology and the Journal of Immunotherapy for Cancer. At the Institute, he leads a team of medical oncologists actively involved in clinical research bringing industry-leading treatments to patients with genitourinary cancers. Before joining Miami Cancer Institute in 2022, Dr. Garje served as an associate professor of medicine in hematology and oncology at the University of Iowa/Holden Comprehensive Cancer Center.Dr. Garje is also the chair for the castration-resistant prostate cancer guidelines committee for the American Society of Clinical Oncology. He leads the committee's work in reviewing research and writing guidelines for prostate cancer treatment. Dr. Garje serves on the editorial board for Current Problems in Cancer and is a reviewer for multiple journals including Journal of Clinical Oncology and Journal of Oncology Practice. Dr. Garje is passionate about providing individual care to each patient because each has a unique journey. He takes time to listen to patients and walks with them throughout their treatment. When he is not treating patients, Dr. Garje enjoys spending time with his family and traveling, always with a camera in hand. He is fluent in English, Hindi, Telugu and Marathi.

Juan Pretell, M.D., is a musculoskeletal oncology surgeon and the chief of musculoskeletal oncology surgery at Miami Cancer Institute. Dr. Pretell specializes in benign and malignant musculoskeletal tumors and skin cancers affecting the musculoskeletal system. He is fluent in English and Spanish.Prior to joining Miami Cancer Institute in 2022, Dr. Pretell worked at University of Miami where he was an Associate Professor of Orthopedic and Faculty of the Orthopedic Surgery residency program and Musculoskeletal Oncology Fellowship. He also was the director of clinical research in the Division of Musculoskeletal Oncology Surgery.Dr. Pretell’s research has been published in high-impact national and international orthopedic and oncology journals. He has been a speaker in national and international meetings, and faculty for international Musculoskeletal Oncology courses. He is an active member of the Musculoskeletal Tumor Society and fellow of the AAOS. He is also a Diplomate of the American Board of Orthopedic Surgeons.Dr. Pretell’s approach to patient care is to view patients and their families as his own family members. He is honest and open about the diagnosis and the treatment options available with the most current, evidence-based medicine. When he is not treating patients, Dr. Pretell enjoys going to arcades, cooking classes and entertainment activities with his oldest stepson and his triplets, watching movies with his oldest daughter, traveling and taking beach walks with his wife. He is also an avid World Cup soccer fan.

Alex Mejia Garcia, M.D., is a board-certified hematologist at Miami Cancer Institute, part of Baptist Health. Dr. Mejia Garcia specializes in treating lymphoma and multiple myeloma. He is fluent in English and Spanish and conversational in Portuguese. Dr. Mejia Garcia joined Miami Cancer Institute from the Cleveland Clinic Taussig Cancer Institute, where he worked in the Department of Hematologic Oncology and Blood Disorders. While at the Cleveland Clinic, he specialized in treating lymphomas, multiple myeloma and specially, researching and studying a subtype of lymphoma called Waldenstrom macroglobulinemia. Dr. Mejia Garcia completed a fellowship in cancer drug development at UT Health San Antonio MD Anderson Cancer Center. During that time, he directed the early-phase drug development for hematological malignancies program at that institution. He also holds formal and specific training in clinical pharmacology and early phase drug development from Thomas Jefferson University. He has served as the conducting principal investigator in several national clinical trials and in industry-sponsored trials for new lymphoma drugs. Dr. Mejia Garcia’s research has been published in numerous peer-reviewed publications, including Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, the European Journal of Cancer, Cancer, and the Journal of Clinical Medicine Research. Dr. Mejia Garcia takes a holistic, team-oriented and patient-centered approach to cancer treatment. He considers not only the disease state, but also each person’s overall health, social support network, culture and treatment goals. He also utilizes the latest in cancer research to provide the best possible treatment options for each patient. He is passionate about making a positive impact in the lives of his patients and their families. Dr. Mejia Garcia believes his focus on patient care should be in helping them understand their disease, treatment options and to develop skills that will bring them grander success in their journey reducing fear, anxiety and stress When he is not treating patients, Dr. Mejia Garcia enjoys computer programming, weightlifting, baseball and trying new restaurants.